• home
• FGF23 ELISA kits available for the US & CA

Biomedica’s FGF23 ELISA kits now available for the US Biotech community at 25% trial discount.

FGF23 (fibroblast growth factor 23) is a 32 kDa protein with 251 amino acids that is proteolytically processed between arginine179 and serine180 to generate N-terminal and C-terminal fragments. FGF23 is mainly secreted by osteocytes and controls phosphate and 1,25(OH)2 vitamin D homeostasis. Epidemiological data suggest that higher FGF23 concentrations are associated with all-cause mortality, cardiovascular mortality, a higher risk of myocardial infarction, stroke and heart failure.
➡️ Learn more: FGF23 – An Overview

FGF23 ELISA kits available for the US & CA

Biomedica’s FGF23 (intact) and FGF23 (C-terminal) ELISA kits

Biomedica’s FGF23 ELISA kits, widely recognized in Europe and Asia, are now also available in the US.

💡 What makes them a game-changer?

✓ MULTI-MATRIX: for plasma, serum, cell-culture
✓ CONVENIENT: 50 µl sample/well, all buffers included
✓ RELIABLE: validated following quality guidelines
✓ COMPARABLE: good correlation with existing kits
✓ EASY HANDLING: 7 prediluted standards, 2 controls
✓ TRUSTED: cited in more than 80 publications

Biomedica offers world-leading quality products at competitive pricing.

FGF23 ELISA kits available for the US & CA

🚨 Don’t miss out and order your trial kit at 25% discount. Promotion extended until June 30, 2025.

➡️ Contact our US partners or CA partner for your study quote.

Related kits: Sclerostin . OPG . Periostin . Vanin-1 . NT-proBNP . NT-proANP 

 

Literature

Non-Classical Effects of FGF23: Molecular and Clinical Features. Martínez-Heredia L, Canelo-Moreno JM, García-Fontana B, Muñoz-Torres M.Int J Mol Sci. 2024 Apr 30;25(9):4875. doi: 10.3390/ijms25094875. PMID: 38732094; PMCID: PMC11084844.

The role of fibroblast growth factor 23 in regulation of phosphate balance. Wilson R, Mukherjee-Roy N, Gattineni J. Pediatr Nephrol. 2024 Dec;39(12):3439-3451. doi: 10.1007/s00467-024-06395-5. Epub 2024 Jun 14. PMID: 38874635.

FGF23 signalling and physiology. Ho BB, Bergwitz C. J Mol Endocrinol. 2021 Feb;66(2):R23-R32. doi: 10.1530/JME-20-0178. PMID: 33338030; PMCID: PMC8782161.

Soluble RANKL is physiologically dispensable but accelerates tumour metastasis to bone.
Asano T. et al., Nat. Metab. 2019, 1: 868–875.

Data from a study by Asano et al. suggest that membrane-bound RANKL is sufficient for most physiological RANKL functions. By contrast, soluble RANKL specifically contributes to bone metastasis by exerting a chemotactic activity in tumour cells expressing RANK thus attracting them to the bone.

Therefore, measurement of the serum RANKL level may help to identify patients who have a high risk of developing bone metastasis and inhibiting soluble RANKL alone may lead to the development of a new therapeutic strategy.

RANKL can easily be measured in serum:

√ HIGH SENSITIVITY – measurable concentrations in healthy subjects
√ Only ELISA that measures free uncomplexed soluble RANKL
√ CE-marked – widely cited in clinical studies

Also available:
OPG ELISA – most referenced

Learn more: RANKL biology: bone metabolism, the immune system, and beyond.
Ono T. et al., Inflamm. Regen. 2020; 40: 2. Full text

Spinal cord injury (SCI) induces an acute alteration in bone metabolism. Although the aetiology of the bone disturbances is not precisely known, immobilisation reduces mechanical loading and the morphology of osteocytes, which are the primary mechanosensors. Periostin and Sclerostin are secreted mostly by osteocytes and are involved in bone’s mechanical response.

In a recent study using the Biomedica Periostin ELISA and Sclerostin ELISA, individuals with spinal cord injury presented higher serum Periostin levels in the acute phase and normal values in the chronic phase.

Conversely, serum Sclerostin levels were suppressed whatever the post-injury duration in the individuals with spinal cord injury. Paraplegia vs. tetraplegia and fragility fracture status seemed to influence Sclerostin levels only.

Maïmoun et al. Periostin and Sclerostin levels in individuals with spinal cord injury and their relationship with bone mass, bone turnover, fracture and osteoporosis status. Bone. 2019 127:612-619.